Oncology · Prostate CancerTrial Updateclinicalmid-term

Pilot Study on Neoadjuvant Dapagliflozin in High-Risk Prostate Cancer

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/2/2026, 12:30:54 AM

Assessment confidence: 60% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The pilot study on dapagliflozin as a neoadjuvant therapy in high-risk prostate cancer could redefine treatment protocols in oncology. Successful outcomes may lead to expanded indications for dapagliflozin, enhancing its market presence beyond diabetes. Regulatory context from FDA (FDA Approves New Treatment That Uses Donor Immune Cells to Prevent Serious Complications in Blood Cancer Patients) supports the near-term read. Assessment grounded in 8 ranked evidence items (2 high-relevance).

Strategic Assessment

The strongest clinical anchor is Neoadjuvant SGLT2 Inhibition in Localized Prostate Cancer (ClinicalTrials.gov), sub-indication match (prostate cancer); entity match (dapagliflozin). In prostate cancer, 0 regulatory and 2 competitive items passed relevance filtering for dapagliflozin. If dapagliflozin proves effective in this new indication, it could capture a significant share of the oncology market, potentially increasing revenue streams for the product.

Competitive Pressure

The most relevant competitive pressure comes from Capivasertib plus Abiraterone Approved for PTEN-Deficient Prostate Cancer (Humanexa Signals) — sub-indication match (prostate cancer). Secondary pressure from FDA ODAC Recommends Truqap for PTEN-Deficient Prostate Cancer. If successful, dapagliflozin could position itself as a novel neoadjuvant therapy in prostate cancer, impacting treatment paradigms.

Regulatory Outlook

Regulatory risk is concentrated around Positive trial results could pave the way for regulatory submissions for new indications, impacting approval timelines and compliance requirements..

Key Risks

Elevated medium regulatory exposure for dapagliflozin could delay market entry or constrain labeling if agency review intensifies.
Evidence gap: no medium- or high-relevance regulatory precedents in ingested corpus.
Clinical risk from ClinicalTrials.gov (Neoadjuvant SGLT2 Inhibition in Localized Prostate Cancer) could weigh on dapagliflozin through efficacy or safety read-through uncertainty if follow-through weakens.
Competitive risk from Humanexa Signals (Capivasertib plus Abiraterone Approved for PTEN-Deficient Prostate Cancer) could weigh on dapagliflozin through competitive crowding and share erosion if follow-through weakens.

Key Opportunities

If dapagliflozin proves effective in this new indication, it could capture a significant share of the oncology market, potentially increasing revenue streams for the product.
The potential for dapagliflozin to expand its indications beyond diabetes into oncology.

What Would Change This Assessment

This becomes more urgent if Monitor results on tolerability, safety, and efficacy in tumor shrinkage from this pilot study.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA Approves New Treatment That Uses Donor Immune Cells to Prevent Serious Complications in Blood Cancer Patients
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Janus Kinase (JAK) inhibitors: Drug Safety Communication - FDA Requires Warnings about Increased Risk of Serious Heart-related Events, Cancer, Blood Clots, and Death
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Ongoing | Cancer Accelerated Approvals
FDAlow relevance
Regulatory pathway relevance (indication); Broad oncology match without sub-indication specificity
FDA document
View source
Withdrawn | Cancer Accelerated Approvals
FDAlow relevance
Regulatory pathway relevance (indication); Broad oncology match without sub-indication specificity
FDA document
View source
Oncology (Cancer)/Hematologic Malignancies Approval Notifications
FDAlow relevance
Broad oncology match without sub-indication specificity
FDA document
View source

Neoadjuvant SGLT2 Inhibition in Localized Prostate Cancer
ClinicalTrials.govhigh relevance
Sub-indication match (prostate cancer); Entity match (dapagliflozin)
FDA document
View source
Efforts to Increase Representation in Prostate Cancer Clinical Trials at Lyndon B.
ClinicalTrials.govmedium relevance
Sub-indication match (prostate cancer)
FDA document
View source
Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
A Study of MRD-Guided Zanubrutinib Plus Sonrotoclax in Treatment-Naïve, High-Risk CLL/SLL Patients
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Cuidar-ME, Web-based Psychological Intervention for (Peri)Menopausal Women: A Pilot Randomized Controlled Trial
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial Cancer
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Comparing Radiation Therapy to Usual Treatment for Patients With High-Risk Bone Metastases That Are Not Causing Pain, PREEMPT Trial
ClinicalTrials.govlow relevance
Broad oncology match without sub-indication specificity
FDA document
View source
Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer
ClinicalTrials.govlow relevance
Broad oncology match without sub-indication specificity
FDA document
View source

Capivasertib plus Abiraterone Approved for PTEN-Deficient Prostate Cancer
Humanexa Signalsmedium relevance
Sub-indication match (prostate cancer)
FDA ODAC Recommends Truqap for PTEN-Deficient Prostate Cancer
Humanexa Signalsmedium relevance
Sub-indication match (prostate cancer)

Gut microbial metabolism of Flutamide attenuates its therapeutic efficacy against prostate cancer.
PubMedhigh relevance
Sub-indication match (prostate cancer); Entity match (prostate cancer treatment)
FDA document
View source
Targeting the PI3K/AKT pathway in prostate cancer: the role of PTEN deficiency and biomarker-guided therapy.
PubMedmedium relevance
Sub-indication match (prostate cancer)
FDA document
View source
MicroRNA-6833-3p drives prostate cancer progression and stemness by targeting the NUMB-mediated NOTCH signaling pathway.
PubMedmedium relevance
Sub-indication match (prostate cancer)
FDA document
View source
First-in-human evaluation of [(18)F]-AlF-NOTA-neurotensin for NTSR1-targeted imaging of prostate cancer: a head-to-head comparison with [(68)Ga]Ga-PSMA-617.
PubMedmedium relevance
Sub-indication match (prostate cancer)
FDA document
View source
Elevated ESR2 and BRCA1 gene expression in adenomyosis associated with endometrial cancer: a pilot study.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Effects of fecal microbiota transplantation and probiotics on the gut microbiome in antibiotic-treated septic patients: A pilot randomized controlled trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
The role of capacitive hyperthermia as an adjunct treatment in oncology: a systematic review of randomized phase III trials.
PubMedlow relevance
Broad oncology match without sub-indication specificity
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

dapagliflozin
prostate cancer treatment

Commercial impact

medium

If dapagliflozin proves effective in this new indication, it could capture a significant share of the oncology market, potentially increasing revenue streams for the product.

Regulatory impact

medium

Positive trial results could pave the way for regulatory submissions for new indications, impacting approval timelines and compliance requirements.

What to watch

Monitor results on tolerability, safety, and efficacy in tumor shrinkage from this pilot study.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.